Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2281-2292

  Ding, Xianting ^a   Sanchez, David Jesse ^a,b   Shahangian, Arash ^a   Al Shyoukh, Ibrahim ^a,c   Cheng, Genhong ^a   Ho, Chih Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combinatorial drug optimization; Drug combination; Drug screening; Feedback system control; FSC; HSV 1

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADVERSE OUTCOME; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY;

ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; DRUG COMBINATIONS; DRUG DISCOVERY; FEEDBACK; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MODELS, BIOLOGICAL; NIH 3T3 CELLS;

HUMAN HERPESVIRUS 1;

EID: 84870359899     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27540     Document Type: Article

References (30)

1. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5(10):821-834.
2. Zheng CJ, Han LY, Yap CW, Ji ZL, Cao ZW, Chen YZ. Therapeutic targets: Progress of their exploration and investigation of their characteristics. Pharmacol Rev. 2006;58(3):259-279.
3. Papp B, Pal C, Hurst LD. Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast. Nature. 2004;429(6992):661-664.
4. Pilpel Y, Sudarsanam P, Church GM. Identifying regulatory networks by combinatorial analysis of promoter elements. Nat Genet. 2001;29(2):153-159.
5. Peng XH, Karna P, Cao ZH, Jiang BH, Zhou MX, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281(36): 25903-25914.
6. Overall CM, Kleifeld O. Tumour microenvironment-Opinion-Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6(3):227-239.
7. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71-U10.
8. Kitano H. Innovation-a robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov. 2007;6(3):202-210.
9. Huang S. Rational drug discovery: what can we learn from regulatory networks? Drug Discov Today. 2002;7(20):S163-S169.
10. Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008;13(10):1114-1119.
11. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. P Natl Acad Sci U S A. 2003;100(13): 7977-7982.
12. O'Hara M, Kiefer D, Farrell K, Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med. 1998;7(6):523-536.
13. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. New Engl J Med. 1995;333(3):137-141.
14. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J. 2003;326(7404):1427-1431.
15. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605): 2127-2137.
16. Koelle DM, Corey L. Herpes simplex: Insights on pathogenesis and possible vaccines. Annu Rev Med. 2008;59:381-395.
17. Burns WH, Santos GW, Saral R, et al. Isolation and characterization of resistant herpes-simplex virus after acyclovir therapy. Lancet. 1982;1(8269):421-423.
18. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004;30(2):115-133.
19. Rong Q, Alexander TS, Koski GK, Rosenthal KS. Multiple mechanisms for HSV-1 induction of interferon alpha production by peripheral blood mononuclear cells. Arch Virol. 2003;148(2):329-344.
20. Chen SH, Oakes JE, Lausch RN. Synergistic anti-HSV effect of tumor-necrosis-factor-alpha and interferon-gamma in human corneal fibroblasts is associated with interferon-beta induction. Antivir Res. 1993;22(1):15-29.
21. Feduchi E, Carrasco L. Mechanism of inhibition of HSV-1 replication by tumor-necrosis-factor and interferon-gamma. Virology. 1991;180(2):822-825.
22. Dempsey PW, Doyle SE, He JQ, Cheng GH. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth F R. 2003;14(3-4):193-209.
23. Wong PK, Yu FQ, Shahangian A, Cheng GH, Sun R, Ho CM. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. P Natl Acad Sci U S A. 2008;105(13):5105-5110.
24. Tsutsui H, Valamehr B, Hindoyan A, et al. An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun. 2011;2:167.
25. Sun CP, Usui T, Yu F, et al. Integrative systems control approach for reactivating Kaposi's sarcoma-associated herpesvirus (KSHV) with combinatory drugs. Integr Biol (Camb). 2009;1(1):123-130.
26. Liu MY, Rakowski B, Gershburg E, et al. ICP0 antagonizes ICP4-dependent silencing of the herpes simplex virus ICP0 gene. Plos One. 2010;5(1):e8837.
27. Elliott G, O'Hare P. Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J Virol. 1999;73(5):4110-4119.
28. Storn R, Price K. Differential evolution-a simple and efficient heuristic for global optimization over continuous spaces. J Global Optim. 1997;11(4):341-359.
29. Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet. 2001;357(9270):1802-1803.
30. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31(4):997-1004.